Биологические свойства и возможности клинического использования мезенхимальных стволовых клеток
https://doi.org/10.17650/1818-8346-2009-0-4-33-44
Аннотация
Метод трансплантации мезенхимальных стволовых клеток (МСК), как аутологичных, так и аллогенных, в последние годы используется в клинической практике для ускорения приживления кроветворных предшественников и профилактики и терапии реакции «трансплантат против хозяина». В обзоре литературы проанализированы данные об эффективности, безопасности и технологических особенностях использования МСК в клинической практике. Обсуждаются биологические свойства МСК, полученных в результате длительного культивирования, и механизмы их взаимодействия с другими клеточными элементами.
Об авторах
О. С. Татаринова
МГУ им. М. В. Ломоносова
Россия
Россия
Москва
Е. Ю. Осипова
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии Минздравсоцразвития России
Россия
Россия
Елена Юрьевна Осипова
Москва
С. А. Румянцев
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии Минздравсоцразвития России
Россия
Россия
Москва
Список литературы
1. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439—41.
2. Le Blanc K., Frassoni F., Ball L. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371(9624):1579—86.
3. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208—13.
4. Le Blanc K., Rasmusson I., Götherström C. et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004;60:307—15.
5. Haynesworth S.E., Baber M.A., Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996;166:585—92.
6. Cheng L., Qasba P., Vanguri P., Thiede M.A. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34+ hematopoietic progenitor cells. J Cell Physiol 2000;184:58—69.
7. Lazarus H.M., Haynesworth S.E., Gerson S.L. et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995;16:557—64.
8. Koc O.N., Gerson S.L., Cooper B.W. et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and cultureexpanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307—16.
9. Horowitz M.M., Gale R.P., Sondel P.M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555—62.
10. Фриденштейн А.Я., Петракова К.В., Куралесова А.И., Фролова Г.П. Клеткипредшественники для остеогенной и кроветворной тканей. Анализ гетеротопных трансплантантов костного мозга. Цитология 1968;5:557—67.
11. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71—74.
12. Pittenger M.F., Mackay A.M., Beck S.C. et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143—7.
13. Sanchez-Ramos J., Song S., Cardozo-Pelaez F. et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000;164:247—56.
14. Caplan A.I., Bruder S.P. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 2001;7:259—64.
15. Schwartz R.E., Reyes M., Koodie L. et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002;109:1291—302.
16. Caplan A.I. Mesenchymal stem cells. J Orthop Res 1991;9:641—50.
17. Horwitz E.M., Le Blanc K., Dominici M. et al. Clarification of the nomenclature for MSC: the international Society for Cellular Therapy position statement. Cytotherapy 2005;7:393—5.
18. Dominici M., Le Blanc K., Mueller I. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315—7.
19. Chichester C.O., Fernandez M., Minguell J.J. Extracellular matrix gene expression by human bone marrow stroma and by marrow fibroblasts. Cell Adhes Commun 1993;1:93—9.
20. Majumdar M.K., Thiede M.A., Mosca J.D. et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998;176:57—66.
21. Majumdar M.K., Banks V., Peluso D.P., Morris E.A. Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J Cell Physiol 2000;185:98—106.
22. Tse W.T., Pendleton J.D., Beyer W.M. et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389—97.
23. Le Blanc K., Tammik L., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Haematol 2003;31:890—6.
24. Klyushnenkova E., Mosca J.D., Zernetkina V. et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005;12:47—57.
25. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235—42.
26. Campagnoli C., Roberts I.A., Kumar S. et al. Identification of mesenchymal stem /progenitor cells in human first — trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396—402.
27. Noort W.A., Kruisselbrink A.B., in't Anker P.S. et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2002;30:870—8.
28. De Ugarte D.A., Morizono K., Elbarbary A. et al. Comparison of multilineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003;174:101—9.
29. Le Blanc K., Ringden O.K. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262(5):509—25.
30. Banfi A., Muraglia A., Dozin B. et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp Hematol 2000;28:707—15.
31. Banfi A., Bianchi G., Notaro R. et al. Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. Tissue Eng 2002;8:901—10.
32. Muraglia A., Cancedda R., Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000;113(7):1161—6.
33. Tremain N., Korkko J., Ibberson D. et al. MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages. Stem Cells 2001;19:408—18.
34. Liechty K.W., MacKenzie T.C., Shaaban A.F. et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;6:1282—6.
35. Pochampally R.R., Neville B.T., Schwarz E.J. et al. Rat adult stem cells (marrow stromal cells) engraft and differentiate in chick embryos without evidence of cell fusion. Proc Natl Acad Sci USA 2004;101:9282—5.
36. Gao J., Dennis J.E., Muzic R.F. et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12—20.
37. Chapel A., Bertho J.M., Bensidhoum M. et al. Mesenchymal stem cells home to injured tissues when coinfused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003;5:1028—38.
38. Devine S.M., Cobbs C., Jennings M. et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999—3001.
39. Crevensten G., Walsh A.J., Ananthakrishnan D. et al. Intervertebral disc cell therapy for regeneration: mesenchymal stem cell implantation in rat intervertebral discs. Ann Biomed Eng 2004;32:430—4.
40. Arinzeh T.L., Peter S.J., Archambault M.P. et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 2003;85A:1927—35.
41. Chamberlain J.R., Schwarze U., Wang P.R. et al. Gene targeting in stem cells from individuals with osteogenesis imperfect. Science 2004;303:1198—201.
42. Toma C., Pittenger M.F., Cahill K.S. et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93—8.
43. Murphy J.M., Fink D.J., Hunziker E.B., Barry F.P. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464—74.
44. Sugaya K. Potential use of stem cells in neuroreplacement therapies for neurodegenerative diseases. Int Rev Cytol 2003;228:1—30.
45. Deng Y., Guo X., Yuan Q., Li S. Efficiency of adenoviral vector mediated CTLA4Ig gene delivery into mesenchymal stem cells. Chin Med J (Engl) 2003;116:1649—54.
46. Ortiz L.A., Gambelli F., McBride C. et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407—11.
47. Togel F., Hu Z., Weiss K. et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005;289:31—42.
48. Zappia E., Casazza S., Pedemonte E. et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755—61.
49. Dexter T.M., Spooncer E., Schofield M. et al. Hematopoietic stem cells and the problem of self-renewal. Blood Cells 1984;10:315—39.
50. Almeida-Porada G., Flake A.W., Glimp H.A., Zanjani E.D. Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol 1999;27:1569—75.
51. Angelopoulou M., Novelli E., Grove J.E. et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 2003;31:413—20.
52. Anker P.S., Noort W.A., Kruisselbrink A.B. et al. Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol 2003;31:881—9.
53. Maitra B., Szekely E., Gjini K. et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004;33:597—604.
54. Владимирская Е.Б. Механизмы кроветворения и лейкемогенеза: Цикл лекций. М.: Династия, 2007.
55. Lee S.T., Jang J.H., Cheong J.W. et al. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002;118:1128—31.
56. Le Blanc K., Samuelsson H., Gustafsson B. et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21(8):1733—8.
57. Bartholomew A., Sturgeon C., Siatskas M. et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42—8.
58. Krampera M., Glennie S., Dyson J. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722—9.
59. Le Blanc K., Tammik L., Sundberg B. et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11—20.
60. Potian J.A., Aviv H., Ponzio N.M. et al. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003;171:3426—34.
61. Beyth S., Borovsky Z., Mevorach D. et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214—9.
62. Angoulvant D., Clerc A., Benchalal S. et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004;41:469—76.
63. Di Nicola M., Carlo-Stella C., Magni M. et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838—43.
64. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005;305:33—41.
65. Liu J., Lu X.F., Wan L. et al. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant Proc 2004;36:3272—5.
66. Sakaguchi S., Sakaguchi N., Asano M. et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151—64.
67. Blazar B.R., Taylor P.A. Regulatory T cells. Biol Blood Marrow Transplant 2005;11:46—9.
68. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815—22.
69. Maccario R., Podesta M., Moretta A. et al. Interaction of human mesenchymal stem cells with cells involved in alloantigenspecific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005;90:516—25.
70. Rasmusson I., Le Blanc K., Sundberg B., Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007;65:336—43.
71. Groh M.E., Maitra B., Szekely E. Koc O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005;33:928—34.
72. Djouad F., Plence P., Bony C. et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837—44.
73. Augello A., Tasso R., Negrini S.M. et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005;35:1482—90.
74. Meisel R., Zibert A., Laryea M. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619—21.
75. Munn D.H., Zhou M., Attwood J.T. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191—3.
76. Akasaki Y., Liu G., Chung N.H. et al. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase- 2-overexpressing glioma. J Immunol 2004;173:4352—9.
77. Arikawa T., Omura K., Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004;200:400—6.
78. Corcione A., Benvenuto F., Ferretti E. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367—72.
79. Friedenstein A., Kuralesova A.I. Osteogenic precursor cells of bone marrow in radiation chimeras. Transplantation 1971;12:99—108.
80. Jiang X.X., Zhang Y., Liu B. et al. Human mesenchymal stem cells inhibit differentiation and function of monocytederived dendritic cells. Blood 2005;105:4120—6.
81. Zhang W., Ge W., Li C. et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte- derived dendritic cells. Stem Cells Dev 2004;13:263—71.
82. Svensson M., Maroof A., Ato M., Kaye P.M. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 2004;21:805—16.
83. Glennie S., Soeiro I., Dyson P.J. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821—7.
84. Ringden O., Rynnel-Dagöö B. Activation of human B and T lymphocytes by protein A of Staphylococcus aureus. Eur J Immunol 1978;8:47—52.
85. Nauta A.J., Westerhuis G., Kruisselbrink A.B. et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108:2114—20.
86. Yanez R., Lamana M.L., Garcia-Castro J. et al. Adipose tissue-derived mesenchymal stem cells (ADMSC) have in vivo immunosuppressive properties applicable for the control of graft-versushost disease (GVHD). Stem Cells 2006;24:2582—91.
87. Sudres M., Norol F., Trenado A. et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graftversus-host disease in mice. J Immunol 2006;176:7761—7.
88. Zhang J., Li Y., Chen J. et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005;195:16—26.
89. Djouad F., Fritz V., Apparailly F. et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005;52:1595— 603.
90. Wu G.D., Nolta J.A., Jin Y.S. et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003;75:679—85.
91. Kunter U., Rong S., Djuric Z. et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006;17:2202—12.
92. Studeny M., Marini F.C., Champlin R.E. et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62:3603—8.
93. Lazarus H.M., Koc O.N., Devine S.M. et al. Cotransplantation of HLA-identical sibling cultureexpanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11:389—98.
94. Ball L.M., Bernardo M.E., Locatelli F. et al. Cotransplantation of haploidentical bone marrow derived mesenchymal stem cells overcomes graft dysfunction and improves hematological and lymphocyte recovery in haploidentical stem cell transplantation. Blood 2006;108: Abstract 3118.
95. Rombouts W.J., Ploemacher R.E. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003;17:160—70.
96. Lin Y.M., Bu L.M., Yang S.J. et al. Influence of human mesenchymal stem cells on cell proliferation and chemo-sensitivity of K562 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14(2):308—12.
97. Zhu Y., Sun Z., Han Q. et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009;23(5):925—33.
98. Ding Y., Lu H., Lu S.F. et al. Effects of human bone marrow mesenchymal stem cells on proliferation and apoptosis of k562 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009;17(1):137—40.
99. Konopleva M., Konoplev S., Hu W. et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002;16(9):1713—24.
100. Lin Y.M., Zhang G.Z., Leng Z.X. et al. Study on the bone marrow mesenchymal stem cells induced drug resistance in the U937 cells and its mechanism. Chin Med J (Engl) 2006;119(11):905—10.
101. Liang R., Huang G.S., Chen X.Q. et al. Effects of human fibroblastoid stromal cell line on proliferation of HL-60 cells and expression of VEGF. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003;11(5):476—9.
102. Liang R., Huang G.S., Wang Z. et al. Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60/VCR. Int J Hematol 2008;87(2):152—66.
103. Ning H., Yang F., Jiang M. et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008;22(3):593—9.
Рецензия
Для цитирования:
Татаринова О.С., Осипова Е.Ю., Румянцев С.А. Биологические свойства и возможности клинического использования мезенхимальных стволовых клеток. Онкогематология. 2009;(4):33-44. https://doi.org/10.17650/1818-8346-2009-0-4-33-44
For citation:
Tatarinova O.S., Osipova E.Yu., Roumiantsev S.A. Mesenchymal stem cells biological properties and possibilities of clinical use. Oncohematology. 2009;(4):33-44. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-4-33-44
Просмотров:
198
Послать статью по эл. почте 